$RPTX
Repare Therapeutics Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022023919 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $18.20M $112.5M $278.0K
YoY Change 164.62% 40383.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.939M $7.904M $6.596M
YoY Change 3.93% 19.83% 57.05%
% of Gross Profit
Research & Development $29.89M $31.24M $25.36M
YoY Change 6.86% 23.19% 151.32%
% of Gross Profit
Depreciation & Amortization $455.0K $484.0K $369.0K
YoY Change 23.64% 31.17% 75.71%
% of Gross Profit
Operating Expenses $37.83M $39.15M $31.96M
YoY Change 6.23% 22.5% 126.85%
Operating Profit $73.40M -$31.68M
YoY Change -331.7% 124.88%
Interest Expense $2.989M $2.153M $86.00K
YoY Change 5648.08% 2403.49% -80.89%
% of Operating Profit 2.93%
Other Income/Expense, Net $13.00K $2.116M $79.00K
YoY Change -165.0% 2578.48% -82.13%
Pretax Income -$16.63M $75.52M -$31.60M
YoY Change -42.06% -338.97% 131.59%
Income Tax $15.03M $54.00K -$708.0K
% Of Pretax Income 0.07%
Net Earnings -$31.66M $75.46M -$30.89M
YoY Change 11.91% -344.27% 124.67%
Net Earnings / Revenue -173.96% 67.05% -11112.23%
Basic Earnings Per Share $1.80 -$0.83
Diluted Earnings Per Share -$0.75 $1.71 -$832.2K
COMMON SHARES
Basic Shares Outstanding 41.96M 41.94M 37.12M
Diluted Shares Outstanding 44.18M 37.12M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $343.9M $155.2M $261.0M
YoY Change 2.84% -40.54% -24.98%
Cash & Equivalents $159.5M $155.2M $261.0M
Short-Term Investments $184.4M $215.2M $7.200M
Other Short-Term Assets $5.715M $5.635M $9.103M
YoY Change -9.49% -38.1% 7.09%
Inventory
Prepaid Expenses $5.715M $5.635M $9.103M
Receivables
Other Receivables $4.323M
Total Short-Term Assets $354.0M $390.6M $280.4M
YoY Change 0.73% 39.31% -22.4%
LONG-TERM ASSETS
Property, Plant & Equipment $4.228M $4.683M $4.165M
YoY Change -24.55% 12.44% -49.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $497.0K $497.0K $1.008M
YoY Change -15.19% -50.69% 44.0%
Total Long-Term Assets $10.10M $18.56M $15.27M
YoY Change -41.64% 21.56% 71.56%
TOTAL ASSETS
Total Short-Term Assets $354.0M $390.6M $280.4M
Total Long-Term Assets $10.10M $18.56M $15.27M
Total Assets $364.1M $409.2M $295.6M
YoY Change -1.26% 38.4% -20.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $461.0K $9.345M $1.860M
YoY Change -79.97% 402.42% 3.33%
Accrued Expenses $23.55M $17.49M $12.08M
YoY Change 17.93% 44.72% 115.77%
Deferred Revenue $53.10M $34.78M $8.925M
YoY Change 345.45% 289.74% 315.12%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $78.62M $61.87M $23.41M
YoY Change 124.06% 164.29% 129.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.939M $41.51M $53.98M
YoY Change -86.86% -23.1% -8.97%
Total Long-Term Liabilities $5.939M $41.51M $53.98M
YoY Change -86.86% -23.1% -8.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $78.62M $61.87M $23.41M
Total Long-Term Liabilities $5.939M $41.51M $53.98M
Total Liabilities $84.56M $103.4M $77.39M
YoY Change 5.31% 33.58% 11.52%
SHAREHOLDERS EQUITY
Retained Earnings -$239.3M -$207.7M -$182.0M
YoY Change 13.81% 14.11%
Common Stock $519.3M $514.0M $400.2M
YoY Change 4.13% 28.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $279.5M $305.8M $218.3M
YoY Change
Total Liabilities & Shareholders Equity $364.1M $409.2M $295.6M
YoY Change -1.26% 38.4% -20.14%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$31.66M $75.46M -$30.89M
YoY Change 11.91% -344.27% 124.67%
Depreciation, Depletion And Amortization $455.0K $484.0K $369.0K
YoY Change 23.64% 31.17% 75.71%
Cash From Operating Activities -$29.64M $88.16M -$32.77M
YoY Change 42.91% -369.0% 62.97%
INVESTING ACTIVITIES
Capital Expenditures -$1.720M -$266.0K -$324.0K
YoY Change 942.42% -17.9% -32.5%
Acquisitions
YoY Change
Other Investing Activities $32.34M -$208.7M -$65.00K
YoY Change -13978.97% 320921.54%
Cash From Investing Activities $34.06M -$208.9M -$389.0K
YoY Change -8657.29% 53609.51% -18.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 165.0K 269.0K 363.0K
YoY Change -99.83% -25.9% -121.35%
NET CHANGE
Cash From Operating Activities -29.64M 88.16M -32.77M
Cash From Investing Activities 34.06M -208.9M -389.0K
Cash From Financing Activities 165.0K 269.0K 363.0K
Net Change In Cash 4.586M -120.5M -32.80M
YoY Change -93.75% 267.4% 47.15%
FREE CASH FLOW
Cash From Operating Activities -$29.64M $88.16M -$32.77M
Capital Expenditures -$1.720M -$266.0K -$324.0K
Free Cash Flow -$27.92M $88.42M -$32.45M
YoY Change 35.7% -372.5% 65.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001808158
CY2021 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
dei Amendment Flag
AmendmentFlag
false
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39335
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
dei Entity Address Address Line1
EntityAddressAddressLine1
7210 Frederick-Banting
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 2A1
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
412-7018
dei Security12b Title
Security12bTitle
Common shares, no par value
dei Trading Symbol
TradingSymbol
RPTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41961510
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155191000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
334427000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
215162000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7439000
CY2022Q3 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2907000
CY2021Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2580000
CY2022Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
629000
CY2021Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
0
CY2022Q3 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
9626000
CY2021Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
0
CY2022Q3 us-gaap Other Receivables
OtherReceivables
1447000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
654000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5635000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6314000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
390597000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
351414000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4683000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5604000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5904000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7491000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
497000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
586000
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
7477000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3620000
CY2022Q3 us-gaap Assets
Assets
409158000
CY2021Q4 us-gaap Assets
Assets
368715000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9345000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2302000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15615000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18622000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2127000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1721000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
34784000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11921000
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
523000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
61871000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35089000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3767000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5592000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
37744000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
39613000
CY2022Q3 us-gaap Liabilities
Liabilities
103382000
CY2021Q4 us-gaap Liabilities
Liabilities
80294000
CY2022Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2021Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41961510
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41961510
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41850162
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41850162
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
481782000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
480699000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32173000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17988000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-524000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-207655000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210266000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
305776000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
409158000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
368715000
CY2022Q3 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
112545000
CY2021Q3 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
278000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
113632000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
723000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31242000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25361000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
89175000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62075000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7904000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6596000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24621000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18574000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
39146000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
31957000
us-gaap Operating Expenses
OperatingExpenses
113796000
us-gaap Operating Expenses
OperatingExpenses
80649000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
73399000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31679000
us-gaap Operating Income Loss
OperatingIncomeLoss
-164000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79926000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
126000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
33000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
250000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-92000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
2027000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
53000
us-gaap Investment Income Net
InvestmentIncomeNet
2700000
us-gaap Investment Income Net
InvestmentIncomeNet
155000
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
37000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
56000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
21000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2116000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
79000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2894000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
42000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
75515000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31600000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2730000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-79884000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3183000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
-174000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-708000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
119000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1266000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
75461000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-30892000
us-gaap Net Income Loss
NetIncomeLoss
2611000
us-gaap Net Income Loss
NetIncomeLoss
-78618000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-524000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-524000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-524000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-524000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
74937000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30892000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2087000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78618000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.80
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.12
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.71
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.12
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41945617
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37122668
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41902554
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37026116
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44177376
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37122668
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44160481
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37026116
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286830000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2057000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
27000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
113000
CY2021Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-26309000
CY2021Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-21417000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
267653000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
449000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
245089000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3693000
CY2021Q3 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-30892000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
218253000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4755000
CY2022Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-34757000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
258660000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
205000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4745000
CY2022Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-38093000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
225517000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5053000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-524000
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
75461000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
305776000
us-gaap Profit Loss
ProfitLoss
2611000
us-gaap Profit Loss
ProfitLoss
-78618000
us-gaap Share Based Compensation
ShareBasedCompensation
14553000
us-gaap Share Based Compensation
ShareBasedCompensation
8933000
us-gaap Depreciation
Depreciation
1523000
us-gaap Depreciation
Depreciation
1103000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
1643000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
1248000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
230000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-10000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
733000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-85000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
3857000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1431000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-676000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2425000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
340000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
295000
rptx Increase Decrease In Collaboration Revenue Receivable
IncreaseDecreaseInCollaborationRevenueReceivable
9626000
rptx Increase Decrease In Collaboration Revenue Receivable
IncreaseDecreaseInCollaborationRevenueReceivable
0
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
831000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-3429000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
616000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7066000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-295000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-1291000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
5166000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
536000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65058000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
29959000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-1152000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
129000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-1672000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-584000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
20994000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-723000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2322000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1525000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6400000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5450000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
213914000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5203000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-209836000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1278000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
283000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
712000
rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
432000
rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
283000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
715000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
995000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-74000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-60000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-179236000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-65401000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
334427000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326396000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155191000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
260995000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
13000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3827000
rptx Deferred Financing Costs In Accruals And Other Current Liabilities
DeferredFinancingCostsInAccrualsAndOtherCurrentLiabilities
0
rptx Deferred Financing Costs In Accruals And Other Current Liabilities
DeferredFinancingCostsInAccrualsAndOtherCurrentLiabilities
104000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2022Q3 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
226196000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
531000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
225672000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9974000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9974000
CY2022Q3 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
300000
CY2021Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
0
CY2022Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
194800000
CY2021Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
0
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2021Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2022Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
500000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
500000
CY2021Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.29
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4479000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4867000
CY2022Q3 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
10265000
CY2021Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
11272000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
616000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
387000
CY2022Q3 rptx Accrued Property And Equipment Purchases
AccruedPropertyAndEquipmentPurchases
0
CY2021Q4 rptx Accrued Property And Equipment Purchases
AccruedPropertyAndEquipmentPurchases
1719000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
255000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
377000
CY2022Q3 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
15615000
CY2021Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
18622000
rptx Number Of Operating Leases
NumberOfOperatingLeases
4
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
614000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
563000
us-gaap Operating Lease Cost
OperatingLeaseCost
1845000
us-gaap Operating Lease Cost
OperatingLeaseCost
1406000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
9000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
22000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
24000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.37
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73433
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.85
us-gaap Variable Lease Cost
VariableLeaseCost
130000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
300000
rptx Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
200000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
32000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
20000
us-gaap Variable Lease Cost
VariableLeaseCost
132000
CY2022Q3 us-gaap Lease Cost
LeaseCost
655000
CY2021Q3 us-gaap Lease Cost
LeaseCost
605000
us-gaap Lease Cost
LeaseCost
2001000
us-gaap Lease Cost
LeaseCost
1563000
us-gaap Operating Lease Payments
OperatingLeasePayments
1334000
us-gaap Operating Lease Payments
OperatingLeasePayments
913000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3827000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M1D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M3D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5322591
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3213667
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.29
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73433
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
399648
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
20.78
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8063177
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.45
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.40
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0289
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0098
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0209
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0073
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M26D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8120
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7610
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7882
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7561
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5053000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3693000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14553000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8933000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5053000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3693000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14553000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8933000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
46300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
75461000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-30892000
us-gaap Net Income Loss
NetIncomeLoss
2611000
us-gaap Net Income Loss
NetIncomeLoss
-78618000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41945617
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37122668
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41902554
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37026116
CY2022Q3 rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Shares Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndSharesIssuableUnderTheEspp
2231759
CY2021Q3 rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Shares Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndSharesIssuableUnderTheEspp
0
rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Shares Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndSharesIssuableUnderTheEspp
2257927
rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Shares Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndSharesIssuableUnderTheEspp
0
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44177376
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37122668
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44160481
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37026116
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.80
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.12
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.71
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.12

Files In Submission

Name View Source Status
0000950170-22-023919-index-headers.html Edgar Link pending
0000950170-22-023919-index.html Edgar Link pending
0000950170-22-023919.txt Edgar Link pending
0000950170-22-023919-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20220930.htm Edgar Link pending
rptx-20220930.xsd Edgar Link pending
rptx-ex10_1.htm Edgar Link pending
rptx-ex10_2.htm Edgar Link pending
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
rptx-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rptx-20220930_def.xml Edgar Link unprocessable
rptx-20220930_lab.xml Edgar Link unprocessable
rptx-20220930_pre.xml Edgar Link unprocessable
rptx-20220930_htm.xml Edgar Link completed
rptx-20220930_cal.xml Edgar Link unprocessable